Pliant Therapeutics, Inc.
PLRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.86
KIRA · Stoqly’s AI analyst, in plain words
- Pliant Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Pliant Therapeutics, Inc. lost $149M in fiscal 2025.
- Free cash flow was −$129M in fiscal 2025, — of revenue.
- Pliant Therapeutics, Inc. has $191M more cash than debt.
Market cap
$53.1M
P/E
—
Revenue
$0.0M
Net income
−$149M
Free cash flow
−$129M
Operating margin
—
Pliant Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$149M
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pliant Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- PLIANT THERAPEUTICS, INC.
- CIK
- 0001746473
Pliant Therapeutics, Inc. · PLRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $7.6M | $9.7M | $1.6M | $0.0M | $0.0M |
| Revenue growth | −81.9% | 27.9% | −83.7% | −100.0% | — |
| Operating margin | −1,288.1% | −1,313.4% | −11,654.7% | — | — |
| Net income | −$97.3M | −$123M | −$161M | −$210M | −$149M |
| Net margin | −1,284.5% | −1,273.3% | −10,211.1% | — | — |
| Diluted EPS | −$2.71 | −$2.94 | −$2.75 | −$3.47 | −$2.43 |
| Cash | |||||
| Cash from operations | −$75.4M | −$94.6M | −$116M | −$156M | −$128M |
| Capital expenditure | $2.0M | $1.8M | $0.9M | $3.8M | $0.4M |
| Free cash flow | −$77.4M | −$96.4M | −$117M | −$159M | −$129M |
| FCF margin | −1,022.1% | −995.3% | −7,422.9% | — | — |
| Share count change | 67.9% | 17.2% | 39.8% | 3.1% | 1.4% |
| Debt and strength | |||||
| Cash and short-term investments | $201M | $331M | $494M | $356M | $191M |
| Debt incl. finance leases | $0.0M | $9.9M | $10.1M | $30.2M | $0.0M |
| Shareholders' equity | $199M | $313M | $474M | $304M | $181M |
| Current ratio | 12.4x | 14.2x | 17.7x | 10.9x | 12.0x |
| Interest coverage | — | −160.8x | −145.3x | −75.5x | −61.1x |
| Returns and quality | |||||
| Return on equity | −40.3% | −48.1% | −41.0% | −54.1% | −61.5% |
| Return on tangible equity | −48.9% | −39.4% | −34.1% | −69.2% | −82.4% |
| Piotroski F-score | 1 | 3 | 4 | 1 | 3 |
| Altman Z'' | 9.0 | 9.2 | 13.4 | −0.8 | −7.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
4 insiders
Of sales under plans
100%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pliant Therapeutics, Inc. · PLRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.86 a share, the company is worth $53.1M.
Source: SEC EDGAR XBRL filings (CIK 0001746473). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.